Lamotrigine Tablet, Film Coated, Extended Release
Product Images NDC 42291-445

15 FDA label images from Avkare · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 42291-445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25mg (443 30 25mg)

25mg (443 30 25mg)
Label for Lamotrigine Extended-Release Tablets USP, 25 mg, by AvKARE. The label indicates a once-a-day dosage with 30 tablets per package. It includes a caution to verify the product dispensed and states that the medication is prescription only (Rx Only).*
FDA Label Image

50mg (444 30 50mg)

50mg (444 30 50mg)
Label for AvKARE Lamotrigine Extended-Release Tablets, USP, 50 mg oral tablets. The label states the medication is to be taken once a day, comes in a bottle of 30 tablets, and is prescription only. The NDC number 42291-444-30 is shown along with caution to verify the product dispensed. Additional manufacturer and storage information is included.*
FDA Label Image

100mg (445 30 100mg)

100mg (445 30 100mg)
Label for Lamotrigine Extended-Release Tablets USP 100 mg, oral film-coated extended-release tablets, by AvKARE. The carton contains 30 tablets for once-a-day use and is prescription-only. Includes caution to verify the dispensed product and dispensing instructions for pharmacists.*
FDA Label Image

200mg (446 30 200mg)

200mg (446 30 200mg)
The image shows the label of AvKARE Lamotrigine Extended-Release Tablets, USP, 200 mg, oral, film-coated, extended-release tablets. The package contains 30 tablets with a once-a-day dosing instruction. The label includes a caution to verify the product dispensed and states Rx only. Manufacturer details and storage instructions are partially visible.*
FDA Label Image

250mg (447 30 250mg)

250mg (447 30 250mg)
Packaging label for Lamotrigine Extended-Release Tablets, USP, 250 mg, oral tablets by AvKARE. The label indicates a once-a-day dosage, contains 30 film-coated extended-release tablets, and includes a caution to verify the product dispensed. It states Rx Only and provides a barcode and NDC 42291-447-30.*
FDA Label Image

300mg (448 30 300mg)

300mg (448 30 300mg)
Label for AvKARE Lamotrigine Extended-Release Tablets, USP 300 mg oral tablets. The label indicates the product is for once-a-day use, contains 30 tablets per bottle, and includes a caution to verify the product dispensed. The NDC 42291-448-30 and manufacturer details are visible on the label.*
FDA Label Image

Structural Formula (Lamotrigine Extended Release Tablets Usp 1)

Structural Formula (Lamotrigine Extended Release Tablets Usp 1)
Chemical structure of lamotrigine, showing a triazine ring with two chlorine atoms and amine groups attached.*
FDA Label Image

Figure 1 (Lamotrigine Extended Release Tablets Usp 2)

Figure 1 (Lamotrigine Extended Release Tablets Usp 2)
A line chart comparing responder rates (equal or greater improvement) and worsening for Lamotrigine Extended-Release versus placebo across percent of patients. The x-axis represents percent of patients (100 to 0) and the y-axis shows responder rate from -100% (worsening) to 100% (improvement). Two lines represent the outcomes for placebo (N=73) and Lamotrigine Extended-Release (N=70).*
FDA Label Image

Figure 2 (Lamotrigine Extended Release Tablets Usp 3)

Figure 2 (Lamotrigine Extended Release Tablets Usp 3)
A line graph comparing responder rates between Lamotrigine Extended-Release (N=116) and placebo (N=120). The vertical axis shows responder rate from -100% (worsening) to 100% (equal or greater improvement), while the horizontal axis represents percent of patients from 100 to 0. Solid line indicates Lamotrigine Extended-Release, and dashed line indicates placebo.*
FDA Label Image

Q (Lamotrigine Extended Release Tablets Usp 4)

Q (Lamotrigine Extended Release Tablets Usp 4)
Lamotrigine extended-release film-coated tablet with strength 100 mg, scored, circular white tablet imprinted with 'A' above '949'. Manufactured by AvKARE.*
FDA Label Image

W (Lamotrigine Extended Release Tablets Usp 5)

W (Lamotrigine Extended Release Tablets Usp 5)
The image shows a round, white extended release tablet film coated with 'A 956' printed on one side. The tablet is identified as Lamotrigine, available in various strengths, labeled by AvKARE for oral use.*
FDA Label Image

R (Lamotrigine Extended Release Tablets Usp 6)

R (Lamotrigine Extended Release Tablets Usp 6)
Lamotrigine 300 mg extended-release film-coated oral tablet imprinted with 'A 958' on one side. The tablet is round and white. Labeler: AvKARE.*
FDA Label Image

Y (Lamotrigine Extended Release Tablets Usp 7)

Y (Lamotrigine Extended Release Tablets Usp 7)
Lamotrigine 100 mg extended release film-coated oral tablet showing the round white tablet embossed with 'A' on the top half and '986' on the bottom half, manufactured by AvKARE.*
FDA Label Image

N (Lamotrigine Extended Release Tablets Usp 8)

N (Lamotrigine Extended Release Tablets Usp 8)
Image of a film-coated extended-release tablet of Lamotrigine, imprinted with 'AN 988'. The tablet is oblong and white in color. This tablet is among the available strengths for Lamotrigine oral tablets by labeler AvKARE.*
FDA Label Image

B (Lamotrigine Extended Release Tablets Usp 9)

B (Lamotrigine Extended Release Tablets Usp 9)
An oval-shaped, white extended-release lamotrigine tablet film coated. It is marked with the imprint "AN 990." The tablet is presumably one of the available strengths from AvKARE's lamotrigine tablet line, intended for oral use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.